Clinical Trial Update: IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study evaluating intravenous immunoglobulin (IVIg) for the treatment of cutaneous lupus erythematosus has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• IVIG (intravenous immunoglobulin)

Snippet

Sponsor: University of California, Irvine | Conditions: Cutaneous Lupus Erythematosus | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2015-08-10